AOC 1001
Myotonic Dystrophy Type 1 (DM1)
Key Facts
About Avidity Biosciences
Avidity Biosciences is a clinical-stage biotech with a mission to profoundly improve lives by delivering a new class of targeted RNA therapeutics. Its core innovation is the AOC platform, which overcomes the historic delivery barriers of oligonucleotide therapies by using antibodies as tissue-specific delivery vehicles. The company is executing a focused strategy, advancing a pipeline of AOCs for rare muscle diseases with high unmet need, aiming to establish clinical proof-of-concept that can unlock the platform's potential across a broad range of therapeutic areas. Recent clinical data readouts have generated significant investor confidence, reflected in its multi-billion dollar valuation.
View full company profileTherapeutic Areas
Other Myotonic Dystrophy Type 1 (DM1) Drugs
| Drug | Company | Phase |
|---|---|---|
| ATX-01 (ArthemiR trial) | ARTHEx Biotech | Phase 1/2 |
| DYNE-101 | Dyne Therapeutics | Phase 1/2 |
| SRP-6004 | Sarepta Therapeutics | Phase 1/2 |
| Undisclosed | Design Therapeutics | Preclinical |
| PGN-EDODM1 | PepGen | Phase 2 |